A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
49actual
Sites
13
Countries
Canada, France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-11 | actual | When the study began enrolling |
| Primary completion | 2025-03-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-06 | actual | The whole study's end, after follow-up |
| First posted | 2023-03-02 | actual | When this record first appeared on the registry |
| Results posted | 2026-03-20 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Nonsegmental Vitiligo With Genital Involvement
Intervention
- Drug: Ruxolitinib Cream — also filed as Opzelura
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Achieving a Genital Vitiligo Noticeability Scale (VNS) of "4 - A Lot Less Noticeable" or "5 - No Longer Noticeable" at Week 48
measured Baseline; Week 48
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-02-28 · 732 KB · Prot_000.pdf
Statistical Analysis Planposted 2024-11-06 · 435 KB · SAP_001.pdf
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed